Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients ...Middle East

OSLO, Norway, Oct. 10, 2024 /PRNewswire/ -- Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis...

Hence then, the article about oncoinvent announces first patient dosed in its phase 2 clinical trial of radspherin in ovarian cancer patients was published today ( Thursday 10/10/2024 - 12:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients )

Also on site :

• 2000s Heavy Metal Rocker Makes $1.5 Million Move Before 2026 Tour
• Iran strikes fully loaded Kuwaiti oil tanker at Dubai port; spill risk flagged
• “Bolivia no duerme”: entre la confianza y el nerviosismo, un país entero espera el repechaje al Mundial 2026